NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SAVA

Cassava Sciences Inc

Jul 11 • 04:00PM ET

2.13

Dollar change -0.03
Percentage change -1.39	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY AVXL SRPT ANVS ACLX PRTA AXSM FATE XERS

| Held by: VTI VXF SCHA VTWO VHT IWC VTWG SCHB BTEC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.51	Insider Own	13.11%	Shs Outstand	48.31M	Perf Week	5.97%
Market Cap	102.90M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	41.98M	Perf Month	-1.84%
Enterprise Value	-14.43M	PEG	-	EPS next Q	-	Inst Own	32.83%	Short Float	16.68%	Perf Quarter	73.17%
Income	-72.79M	P/S	-	EPS this Y	-	Inst Trans	-7.57%	Short Ratio	6.50	Perf Half Y	-29.47%
Sales	0.00M	P/B	0.81	EPS next Y	-	ROA	-49.07%	Short Interest	7.00M	Perf YTD	-9.75%
Book/sh	2.64	P/C	0.88	EPS next 5Y	-	ROE	-70.59%	52W High	42.20 -94.95%	Perf Year	-81.56%
Cash/sh	2.43	P/FCF	-	EPS past 3/5Y	-21.17% -40.61%	ROIC	-57.04%	52W Low	1.15 85.22%	Perf 3Y	-91.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.71% 5.49%	Perf 5Y	-28.28%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-30.52%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-82.61%
Dividend Ex-Date	Dec 13, 2012	Quick Ratio	9.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.58	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.08	EPS Q/Q	-14.07%	SMA20	7.09%	Beta	-2.06	Target Price	2.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.18%	Rel Volume	0.36	Prev Close	2.16
Employees	30	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-73.02%	Avg Volume	1.08M	Price	2.13
IPO	Jul 14, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	388,986	Change	-1.39%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-26-24	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-08-24	Upgrade	H.C. Wainwright	Neutral → Buy	$116
Jul-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-16-22	Downgrade	B. Riley Securities	Buy → Neutral	$44
Jul-15-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$100
Jul-07-21	Reiterated	Maxim Group	Buy	$80 → $190
Apr-27-21	Initiated	B. Riley Securities	Buy	$78
Feb-16-21	Reiterated	H.C. Wainwright	Buy	$20 → $66
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$24
Sep-23-20	Upgrade	H.C. Wainwright	Neutral → Buy	$20
May-18-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-20	Downgrade	Maxim Group	Buy → Hold
Jan-10-20	Reiterated	Maxim Group	Buy	$3 → $12

Show Previous Ratings

Jun-30-25 07:00AM	Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting (GlobeNewswire)
May-08-25 08:00AM	Cassava Reports Q1 2025 Financials Results, Provides Business Update (GlobeNewswire) +8.97%
May-01-25 07:30AM	Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
07:30AM	Cassava Appoints Angelique Bordey, PhD, to Enhance Preclinical Program in TSC (GlobeNewswire)
Apr-21-25 04:30PM	Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development (GlobeNewswire) +8.90%
09:35AM	Loading…
Apr-01-25 09:35AM	Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround (Zacks) -8.00%
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks) -9.09%
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks) -7.89%
07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
Mar-25-25 08:05AM	Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data (GlobeNewswire) -32.14%
Mar-20-25 06:18PM	Cassava Sciences: Downside From Alzheimer's Results Still Possible Despite New Developments (SeekingAlpha)
Mar-05-25 11:20AM	H.C. Wainwright focused on what results from Cassavas ReFocus-ALZ might reveal (TipRanks)
Mar-03-25 07:30AM	Cassava Sciences Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Cassava Sciences Licenses Simufilam Method of Treatment Patent (GlobeNewswire) +13.04%
Jan-16-25 01:56PM	Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
12:15PM	Loading…
Jan-13-25 12:15PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights SAVA (GlobeNewswire)
Jan-07-25 04:30PM	Cassava Sciences Provides a Business Update (GlobeNewswire) -6.46%
Dec-27-24 05:45AM	Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA (PR Newswire)
Dec-16-24 02:55PM	Cassava Sciences, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky for More Information SAVA (GlobeNewswire)
Nov-25-24 04:15PM	Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops (Investor's Business Daily) -83.78% -10.94%
03:57PM	Cassava Sciences plummets over 80% on Alzheimer's trial fail (Yahoo Finance Video)
09:19AM	Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study (Investopedia)
07:30AM	Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints (GlobeNewswire)
Nov-24-24 08:01PM	Cassava Sciences to Hold Corporate Update on November 25th (GlobeNewswire)
Nov-18-24 08:30AM	Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer (GlobeNewswire)
Nov-07-24 07:55AM	Cassava Sciences Reports Q3 2024 Financial and Operating Results (GlobeNewswire)
Oct-31-24 08:30AM	Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 (GlobeNewswire)
Oct-17-24 09:19PM	Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge (Insider Monkey)
Oct-09-24 08:29AM	Cassava Sciences Advances Alzheimers Trials Amid SEC Settlement (TipRanks)
Sep-27-24 03:36PM	Cassava Sciences agrees to $40M SEC fine over Alzehimer's claims (Yahoo Finance Video) -10.62%
10:10AM	Loading…
10:10AM	Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims (Investopedia)
Sep-26-24 06:15PM	Cassava Sciences Resolves SEC Investigation (GlobeNewswire)
Sep-24-24 08:30AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire) +9.54%
Sep-09-24 08:30AM	Cassava Sciences Names Rick Barry as Chief Executive Officer (GlobeNewswire)
Sep-03-24 08:31AM	Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 10:44PM	Silicon Motion Technology Corporation (SAVA): Evaluating Its Position Among Top Debt-Free Stocks (Insider Monkey)
08:22AM	7 Best Debt Free Stocks To Buy (Insider Monkey)
Aug-08-24 08:00AM	Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates (GlobeNewswire) -13.84%
Aug-06-24 10:00AM	Cassava Sciences News: Why Is SAVA Stock Trending Today? (InvestorPlace) -13.08%
Aug-05-24 09:01AM	Cassava Sciences Mourns the Death of Board Member Sanford Sandy Robertson (GlobeNewswire) +20.51%
Aug-01-24 08:30AM	Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET (GlobeNewswire) +5.72%
Jul-30-24 08:15AM	Cassava Sciences Announces Expansion of Open-Label Extension Trials (GlobeNewswire)
Jul-17-24 12:26PM	SOUN Stock: Sports Bar Chain Rolls Out Voice Tech From SoundHound AI (InvestorPlace) -29.27%
08:00AM	Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives (GlobeNewswire)
Jul-08-24 04:45PM	3 Healthcare Stocks to Sell in July Before They Crash & Burn (InvestorPlace) +17.38%
Jul-05-24 07:30AM	3 Biotech Stocks to Sell in July Before They Crash & Burn (InvestorPlace) -5.15%
Jul-04-24 07:47AM	Jim Cramer's Latest Stock Portfolio: Top 10 Recommendations (Insider Monkey)
Jul-01-24 03:54PM	Cassava forms committee after US probe, researcher fraud (Yahoo Finance Video)
01:30PM	Stocks to Watch Monday: Chewy, Boeing, NIO, Cassava Sciences (The Wall Street Journal)
11:20AM	Planet Labs Layoffs 2024: What to Know About the Latest Planet Job Cuts (InvestorPlace)
10:40AM	SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud (InvestorPlace)
Jun-28-24 06:14PM	Cassava Sciences Adviser Indicted on Fraud Charges (The Wall Street Journal) -34.83%
03:58PM	Cassava Sciences Issues Statement on Former Science Advisor (GlobeNewswire)
Jun-27-24 03:38PM	Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich (InvestorPlace)
May-23-24 09:55AM	Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
May-10-24 08:53PM	SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024 (InvestorPlace)
04:02PM	Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam (GlobeNewswire)
May-08-24 11:00AM	Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution (GlobeNewswire)
May-01-24 09:10AM	Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ (GlobeNewswire)
Apr-30-24 01:16PM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks (InvestorPlace)
Apr-15-24 09:20AM	Redemption Date Announced for Warrants (GlobeNewswire) -12.04%
Mar-25-24 09:13AM	Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials (GlobeNewswire)
Mar-13-24 10:45AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava (PR Newswire)
Mar-04-24 09:15AM	Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference (GlobeNewswire)
Feb-28-24 09:14AM	Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Feb-23-24 11:30AM	CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Feb-08-24 10:39AM	Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial (InvestorPlace)
Feb-07-24 09:08AM	No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months (GlobeNewswire) +7.35%
Feb-05-24 02:35PM	Cassava Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Jan-05-24 11:46AM	New SAVAW Warrants Are Trading After Cassava Sciences' Distribution (InvestorPlace)
09:12AM	Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool)
Dec-15-23 06:06PM	Why Cassava Sciences Stock Zoomed 21% Higher This Week (Motley Fool)
Dec-13-23 11:10AM	Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days (Investor's Business Daily)
Dec-12-23 02:02PM	Why Is Cassava Sciences (SAVA) Stock Up 15% Today? (InvestorPlace) +5.96%
09:13AM	Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders (GlobeNewswire)
Dec-08-23 07:31PM	Why Cassava Sciences Stock Soared Today (Motley Fool) +17.37% +13.57%
Dec-07-23 04:01PM	Cassava Sciences Appoints Three New Members to its Board of Directors (GlobeNewswire)
Nov-14-23 09:53PM	7 High-Risk, High-Reward Stocks for the Extreme Contrarian (InvestorPlace) +13.90%
Nov-07-23 09:39AM	Cassava Sciences Inc (SAVA) Reports Q3 2023 Financial Results (GuruFocus.com)
09:01AM	Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire)
Nov-06-23 09:15AM	Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer's Disease (GlobeNewswire) -5.81%
Oct-31-23 08:15AM	1 Big Red Flag to Fear When a Stock Is Down (Motley Fool) +6.39%
Oct-25-23 09:15AM	MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA) (GlobeNewswire) +25.80%
Oct-19-23 09:59AM	7 Stocks That Are Heading for a Train Wreck (InvestorPlace) +5.32%
Oct-16-23 07:01PM	Is This The End Of Naked Short Selling? (Oilprice.com) -14.94% +13.21%
05:26PM	SAVA Stock Continues to Plunge on Misconduct Allegations (InvestorPlace)
Oct-13-23 03:29PM	Cassava Sciences Adviser Found to Have Committed Egregious Misconduct (The Wall Street Journal) -15.28%
03:29PM	Alzheimers Researcher Found to Have Committed Misconduct (The Wall Street Journal)
12:45PM	Why Cassava Sciences Stock Is Tanking Today (Motley Fool)
11:21AM	SAVA Stock Alert: Cassava Sciences Addresses Leaked Report (InvestorPlace)
Oct-12-23 11:43PM	Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press (GlobeNewswire)
Oct-06-23 03:13PM	Why Shares of Cassava Sciences Soared This Week (Motley Fool)
Oct-05-23 09:15AM	Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY (GlobeNewswire)
Oct-02-23 09:00AM	Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer's Disease (GlobeNewswire)
Sep-18-23 09:15AM	Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimers Disease (GlobeNewswire) -5.31%
Sep-14-23 06:30AM	The 7 Best Meme Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-13-23 05:20PM	Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimers Disease (GlobeNewswire)
Sep-11-23 09:10AM	Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimers Disease (GlobeNewswire)
Sep-06-23 09:15AM	Cassava Sciences Invited to Present in Four Upcoming Investor Conferences (GlobeNewswire)

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kupiec James William	Chief Medical Officer	Nov 29 '24	Sale	3.87	4,000	15,480	0	Dec 03 04:18 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Option Exercise	1.18	50,000	59,000	71,300	Dec 03 04:16 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Sale	3.86	59,800	230,828	11,500	Dec 03 04:16 PM
Schoen Eric	Chief Financial Officer	Nov 29 '24	Sale	3.82	2,000	7,640	0	Dec 03 04:16 PM
Schoen, Eric J. (SAVA)	Officer	Nov 29 '24	Proposed Sale	3.82	2,000	7,640		Dec 02 05:14 PM
Schoen Eric	Officer	Nov 29 '24	Proposed Sale	3.86	59,800	230,966		Nov 29 03:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SAVA

Cassava Sciences Inc

Upgrade your FINVIZ experience